Drugs / Recombinant Human Luteinizing Hormone
Recombinant Human Luteinizing Hormone
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04037605 | Feb 2020 → Jul 2022 overdue | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03142893 | May 2017 → Oct 2020 overdue | — | Peter y. Liu | Active not recruiting | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01110707 | Jan 2005 → Nov 2006 | infertility disorder, ovarian disorder | Merck KGaA, Darmstadt, Germany | Completed | Missed primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT01071200 | Mar 2005 → Apr 2009 | — | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 3 | NCT01084265 | Feb 2004 → Dec 2005 | hypogonadism | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human Luteinizing Hormone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01071200 ↗ |
| Known as | luveris | “Recombinant Human Luteinizing Hormone (also known as luveris)” NCT04037605 ↗ |
| Known as | Luveris (r-hLH) | “Luveris (r-hLH)” NCT01084265 ↗ |
| Known as | r-hLH | “recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation” NCT01110707 ↗1“Recombinant human luteinizing hormone (r-hLH)” NCT01084265 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human Luteinizing Hormone” NCT01071200 ↗ |
| Route | Subcutaneous | “One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily” NCT01071200 ↗ |